首页 › 基金 › Bain Capital Life Sciences Investors, LLC › NAMS
Bain Capital Life Sciences Investors, LLC 对 NAMS 的持仓历史
NEWAMSTERDAM PHARMA COMPANY · 医疗保健
Bain Capital Life Sciences Investors, LLC 在 Q3 2026 的 13F 申报中披露持有 NAMS(NEWAMSTERDAM PHARMA COMPANY)3,806,559 股,市值约 US$92.6M,约占其申报组合的 6.37%,在其申报持仓中市值排名第 5 位。 Bain Capital Life Sciences Investors, LLC 最近 13 个申报季度中有 13 个季度披露了 NAMS 持仓,最早可追溯至 Q3 2023。
最后更新: 2026-11-16 · 来源: SEC EDGAR Form 13F-HR
Bain Capital Life Sciences Investors, LLC 对 NAMS 的持仓演变
Bain Capital Life Sciences Investors, LLC 于 Q3 2023 首次披露 NAMS 持仓:10,473,913 股(约 US$96.9M)。 该持仓在 Q3 2025 达到峰值 10,719,110 股,市值约 US$304.9M。 在 13 次申报中,Bain Capital Life Sciences Investors, LLC 1 次增持、2 次减持、9 次保持不变。 最近一期申报(Q3 2026)显示持股 3,806,559 股、市值约 US$92.6M。 持仓曾出现大幅变动:Q4 2025 减持约 32% (随后一个季度股价下跌 9%)、Q2 2026 减持约 48% (随后一个季度股价下跌 32%)。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q3 2023 | 10.47M | $96.88M | 新进 |
| Q4 2023 | 10.47M | $116.99M | 持有 |
| Q1 2024 | 10.47M | $247.71M | 持有 |
| Q2 2024 | 10.47M | $201.20M | 持有 |
| Q3 2024 | 10.47M | $173.87M | 持有 |
| Q4 2024 | 10.72M | $275.48M | 增持 |
| Q1 2025 | 10.72M | $219.42M | 持有 |
| Q2 2025 | 10.72M | $194.12M | 持有 |
| Q3 2025 | 10.72M | $304.85M | 持有 |
| Q4 2025 | 7.31M | $256.31M | 减持 |
| Q1 2026 | 7.31M | $233.88M | 持有 |
| Q2 2026 | 3.81M | $129.00M | 减持 |
| Q3 2026 | 3.81M | $92.58M | 持有 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 NAMS 与 13F 数据
NAMS(NEWAMSTERDAM PHARMA COMPANY)属于医疗保健行业。我们追踪的基金中还有 39 只申报持有 NAMS,申报仓位最大的包括:Frazier Life Sciences Management, L.P. (US$613.0M), RA CAPITAL MANAGEMENT, L.P. (US$323.7M), FCPM III SERVICES B.V. (US$206.5M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 NAMS 的基金
- Frazier Life Sciences Management, L.P. 18.09M 股 · $613.03M · Q2 2026
- RA CAPITAL MANAGEMENT, L.P. 9.55M 股 · $323.66M · Q2 2026
- FCPM III SERVICES B.V. 8.49M 股 · $206.49M · Q3 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 4.26M 股 · $144.53M · Q2 2026
- Maverick 资本 3.27M 股 · $110.75M · Q2 2026
- MAVERICK CAPITAL LTD 3.27M 股 · $110.75M · Q2 2026
- Duquesne Family Office LLC 3.07M 股 · $104.05M · Q2 2026
- Medicxi Ventures Management (Jersey) Ltd 2.18M 股 · $53.07M · Q3 2026
- Castle Hook Partners LP 1.37M 股 · $46.46M · Q2 2026
- First Turn Management, LLC 702.40K 股 · $17.08M · Q3 2026
- NWI MANAGEMENT LP 702.00K 股 · $17.07M · Q3 2026
- Cormorant Asset Management, LP 500.00K 股 · $16.95M · Q2 2026
更多关于 Bain Capital Life Sciences Investors, LLC
常见问题
How long has Bain Capital Life Sciences Investors, LLC held NAMS?
Bain Capital Life Sciences Investors, LLC has disclosed NAMS holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is Bain Capital Life Sciences Investors, LLC's current position in NAMS?
As of Q3 2026, Bain Capital Life Sciences Investors, LLC holds 3.81M shares of NAMS (NEWAMSTERDAM PHARMA COMPANY), valued at $92.58M, representing 6.37% of its reported portfolio and ranking #5.
Has Bain Capital Life Sciences Investors, LLC been buying or selling NAMS?
In the latest 13F filing (Q3 2026), Bain Capital Life Sciences Investors, LLC held unchanged its position in NAMS. The position peaked in Q3 2025 at 10.72M shares.
Which other funds hold NAMS?
Other major institutional holders of NAMS include Frazier Life Sciences Management, L.P., RA CAPITAL MANAGEMENT, L.P., FCPM III SERVICES B.V., among 39 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.